AVLAYAH represents Denali’s first commercial product and platform validation. Traders should monitor launch execution, pricing, patient uptake, and PRV monetization plans. Confirmatory trial data from COMPASS will be critical for full approval and long-term commercial viability.
Price Chart
Executive Summary
Denali Therapeutics announced FDA accelerated approval of AVLAYAH™ (tividenofusp alfa-eknm), the first biologic therapy designed to cross the blood-brain barrier for the treatment of neurologic manifestations of Hunter syndrome (MPS II). The approval is based on biomarker reduction in cerebrospinal fluid heparan sulfate, with a confirmatory Phase 2/3 trial ongoing. Denali also received a Rare Pediatric Disease Priority Review Voucher (PRV) as part of the approval.
Key Facts
- FDA granted accelerated approval to AVLAYAH™ for neurologic manifestations of Hunter syndrome (MPS II), a rare lysosomal storage disease.
- AVLAYAH is the first FDA-approved therapy engineered to cross the blood-brain barrier via Denali’s TransportVehicle™ platform targeting the transferrin receptor.
- Approval based on 91% reduction in cerebrospinal fluid heparan sulfate (CSF HS) by week 24 in a Phase 1/2 trial, with 93% of patients reaching normal CSF HS levels.
- Denali received a Rare Pediatric Disease Priority Review Voucher (PRV), which can be sold or used to accelerate review of a future drug application.
- AVLAYAH is indicated for pediatric patients weighing at least 5 kg with early-stage disease; confirmatory Phase 2/3 COMPASS trial is ongoing.
Financial Impact
Potential blockbuster revenue given first-in-class status and unmet need; PRV could be worth $100M+ if sold.
Risk Factors
- Accelerated approval requires verification of clinical benefit in ongoing COMPASS trial; failure could lead to withdrawal.
- Safety concerns including anaphylaxis, infusion reactions, anemia, and membranous nephropathy may limit adoption.
- Competition from gene therapies or next-generation ERTs in development for MPS II.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3262412 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 9, 2026 23d ago | Insider Cluster | $21.57 $20.06 | ▼ −7.00% | ▼ −6.34% | $20.00 (−7.28%) |
Sep 4, 2026 27d ago | Insider Cluster | $22.08 $20.38 | ▼ −7.70% | ▼ −6.58% | $20.00 (−9.42%) |
Aug 6, 2026 8w ago | 8-K | $24.83 $24.40 | ▼ −1.73% | ▼ −2.13% | $20.00 (−19.45%) |
Jul 27, 2026 9w ago | Press Release | $24.05 $23.15 | ▲ +3.74% | ▲ +6.01% | $20.00 (+16.84%) |
Jun 18, 2026 15w ago | 8-K | $23.31 $24.73 | ▲ +6.09% | ▲ +7.76% | $20.00 (−14.20%) |
Jun 18, 2026 15w ago | Press Release | $23.31 $24.73 | ▲ +6.09% | ▲ +7.76% | $20.00 (−14.20%) |
Jun 11, 2026 16w ago | Institutional Cluster | $21.02 $23.49 | ▲ +11.75% | ▲ +11.32% | $20.00 (−4.85%) |
May 21, 2026 19w ago | Press Release | $18.64 $20.41 | ▼ −9.50% | ▼ −7.84% | $20.00 (−7.30%) |
May 7, 2026 21w ago | Press Release | $19.62 $19.39 | ▼ −1.17% | ▼ −2.64% | $20.00 (+1.94%) |
Apr 3, 2026 26w ago | 8-K | $19.38 $19.42 | ▲ +0.21% | ▼ −3.93% | $20.00 (+3.20%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access